OncoHost to Present New Data on PROphetNSCLC at WCLC 2026
OncoHost announced it will present new data for its PROphetNSCLC® test at the World Conference on Lung Cancer in September 2026. The study shows that the proteomics-based assay maintains predictive performance even when blood samples are collected after treatment initiation, rather than only before therapy begins. The findings suggest that PROphetNSCLC®, which helps guide immunotherapy decisions for advanced non-small cell lung cancer patients, can be reliably used in real-world clinical settings where baseline sampling may not always occur. The data indicate strong consistency of the test results across different time points during treatment cycles with chemotherapy or immunotherapy. The study analyzed plasma samples from NSCLC patients at three stages: before therapy, after one cycle of chemotherapy but prior to ICI initiation, and following a single cycle of ICI-based treatment.